Induction-related cost of patients with acute myeloid leukaemia in France
- 267 Downloads
Objective The economic profile of acute myeloid leukaemia (AML) is badly known. The few studies published on this disease are now relatively old and include small numbers of patients. The purpose of this retrospective study was to evaluate the induction-related cost of 500 patients included in the AML 2001 trial, and to determine the explanatory factors of cost. Setting “Induction” patient’s hospital stay from admission for “induction” to discharge after induction. Method The study was performed from the French Public Health insurance perspective, restrictive to hospital institution costs. The average management of a hospital stay for “induction” was evaluated according to the analytical accounting of Besançon University Teaching Hospital and the French public Diagnosis-Related Group database. Multiple linear regression was used to search for explanatory factors. Main outcome measure Only direct medical costs were included: treatment and hospitalisation. Results Mean induction-related direct medical cost was estimated at €41,852 ± 6,037, with a mean length of hospital stay estimated at 36.2 ± 10.7 days. After adjustment for age, sex and performance status, only two explanatory factors were found: an additional induction course and salvage course increased induction-related cost by 38% (±4) and 15% (±1) respectively, in comparison to one induction. These explanatory factors were associated with a significant increase in the mean length of hospital stay: 45.8 ± 11.6 days for 2 inductions and 38.5 ± 15.5 if the patient had a salvage course, in comparison to 32.9 ± 7.7 for one induction (P < 10−4). This result is robust and was confirmed by sensitivity analysis. Conclusion Consideration of economic constraints in health care is now a reality. Only the control of length of hospital stay may lead to a decrease in induction-related cost for patients with AML.
KeywordsAcute myeloid leukaemia Cost Economic burden Explanatory factors France Induction
We would like thank all centres contributing to this study and transmitting data from the French PMSI: Toulouse, Bordeaux, Nancy, Rennes, Strasbourg, Angers, Clermont-Ferrand, Besançon, Limoges, Saint Etienne, Nice, Tours, Dijon, Avignon, Colmar et Nîmes. We also thank Ms Pamela Albert for English assistance in the correction of the manuscript.
Conflicts of interest
The authors declare no conflict of interest with regard to this publication.
- 1.Bishop Y, Fienberg S, Holland P. Discrete multivariate analysis: theory and practice. Cambridge, MA: The MIT Press; 1975. p. 492–7.Google Scholar
- 7.Lioure B, Pigneux A, Recher C, Witz F, Lamy T, Fegueux N et al. No Benefit of Adding High-Dose Melphalan (HDM) Suppported by Autologous Stem Cell Transplantation (SCT) over Treatment with Conventional Induction, HD ARAC Consolidation, and Auto SCT (Busulfan + HDM) for Acute Myelogenous Leukemia (AML) under 60: First Results of the Randomized AML 2001 Trial. Blood. 2006; 108(11):abstract 608.Google Scholar
- 10.Marie JP, Bisserbe S, Bouaziz C, Wdowick T, Zittoun R. A program for medical use of information systems. Validity of calculation of direct costs for the initial treatment of acute myeloblastic leukemia. Presse Med. 1992;21(29):1364–8.Google Scholar
- 14.Stalfelt AM, Brodin H. Costs over time in conventional treatment of acute myeloid leukaemia. A study exploring changes in treatment strategies over two decades. J Intern Med. 1994;236(4):401–9.Google Scholar
- 17.Uyl-de Groot Ca, Lowenberg B, Vellenga E, Suciu S, Willemze R, Rutten FF. Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia. Br J Haematol. 1998;100(4):629–36.Google Scholar